Breast DCEMRI signal is standardized for variable imaging protocols and the linear rate of background parenchymal enhancement (BPE) is calculated, to quantitatively and objectively describe changes in BPE rates following preventative tamoxifen treatment. This is in contrast with the current practice of using 4 subjective categories to describe BPE. Decreased BPE rates post-treatment agree with earlier results showing that BPE, like breast density, correlates with breast cancer risk. Standardization for imaging parameters and contrast agent relaxivity increases the observed effect size, pointing to increased sensitivity to treatment-induced changes and the potential as a tool for individual breast cancer risk management.
This abstract and the presentation materials are available to members only; a login is required.